4//SEC Filing
SYNAGEVA BIOPHARMA CORP 4
Accession 0001246360-15-002048
CIK 0000911326operating
Filed
May 7, 8:00 PM ET
Accepted
May 8, 5:07 PM ET
Size
19.7 KB
Accession
0001246360-15-002048
Insider Transaction Report
Form 4
Williams Glen
SVP, Technical Operations
Transactions
- Sale
Common Stock
2015-05-06$204.94/sh−400$81,976→ 1,068 total - Exercise/Conversion
Common Stock
2015-05-06$57.56/sh+833$47,947→ 2,134 total - Exercise/Conversion
Common Stock
2015-05-06$40.32/sh+833$33,587→ 1,301 total - Sale
Common Stock
2015-05-06$206.97/sh−100$20,697→ 568 total - Exercise/Conversion
Stock Option (Right to Buy)
2015-05-06−833→ 20,835 totalExercise: $40.32Exp: 2023-06-06→ Common Stock (833 underlying) - Sale
Common Stock
2015-05-06$203.99/sh−666$135,857→ 1,468 total - Exercise/Conversion
Stock Option (Right to Buy)
2015-05-06−833→ 14,167 totalExercise: $57.56Exp: 2022-10-04→ Common Stock (833 underlying) - Sale
Common Stock
2015-05-06$206.27/sh−400$82,508→ 668 total - Sale
Common Stock
2015-05-06$215.26/sh−100$21,526→ 468 total
Footnotes (8)
- [F1]The stock option exercise and sale of shares of the Company's common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2015.
- [F2]25% of the total number of shares subject to the option vest and become exercisable on 06/06/2014 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter.
- [F3]25% of the total number of shares subject to the option vest and become exercisable on 09/24/2013 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter.
- [F4]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $203.37 to $204.30. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- [F5]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $204.60 to $205.18. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- [F6]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $205.87 to $206.83. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- [F7]This transaction was executed through a broker-dealer at a price of $206.97.
- [F8]This transaction was executed through a broker-dealer at a price of $215.26.
Documents
Issuer
SYNAGEVA BIOPHARMA CORP
CIK 0000911326
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000911326
Filing Metadata
- Form type
- 4
- Filed
- May 7, 8:00 PM ET
- Accepted
- May 8, 5:07 PM ET
- Size
- 19.7 KB